Pseudomonas aeruginosa VIM-2 (CDC & FDA AR Isolate Bank #0108), Lung Infection Model, CFU Data

ITEM 608647

CONTACT FOR PRICING

STATUS Available

CONTACT CUSTOMER SERVICE

^{ADD TO FAVORITES}

^{ADD TO PANEL}

OVERVIEW

DOCUMENTS/REFERENCES

RELATED SERVICES

RELATED PRODUCTS

BIOLOGICAL INFORMATION

BACKGROUND INFORMATION

This assay assesses the antimicrobial efficacy of test articles in a lung infection model with a carbapenem resistant strain. The microbial counts in tissue are measured. P. aeruginosa can cause life-threatening lung, wound, and urinary tract infections as well as peritonitis and septicemia. This carbapenem resistant strain carries the following antimicrobial resistance (AMR) genes: aac(3)-Id, aadA2, cmlA1, dfrB5, OXA-4, OXA-50, PAO, tet(G) and VIM-2. The carbapenem resistance may be due to expression of the VIM-2 metallo beta-lactamase. It is resistant to beta-lactam antibiotics, aminoglycosides, and quinolones. It is susceptible to aztreonam and colistin. The FDA-CDC Antimicrobial Resistance Isolate Bank supplied this strain and the genome sequence annotation of AMR genes.

SPECIES

Pseudomonas aeruginosa

STRAIN COMMON NAME

(#0108)

ORGANISM

Gram-negative Bacteria

INCUBATION CONDITIONS

Aerobic

NOTABLE ANTIBIOTIC RESISTANCE GENE

VIM-2

ANTIBIOTIC RESISTANCE GENES

aac(3)-Id,aadA2,cmlA1,dfrB5,OXA-4,OXA-50,PAO,tet(G),ÿVIM-2

SOURCE

STRAIN SOURCE

CDC & FDA AR Isolate Bank

STRAIN SOURCE ID

AR Bank #0108

ASSAY INFORMATION

ASSAY TYPE

In Vivo

TESTING INFORMATION

PROCEDURE SUMMARY

Groups of 5 neutropenic mice are used. Animals are intranasally inoculated with pathogen suspension then test articles or vehicle are administered at time points after inoculation. Doses may be administered IV, SC, PO, IM, IP or by IV infusion. At 24 hours after the first treatment, animals are humanely euthanized and tissue is aseptically removed. Tissue is homogenized and pathogen counts are determined by plating to agar medium. Pathogen counts from treatment groups are compared to vehicle groups and the significance of an effect is determined.

CRITERIA FOR SIGNIFICANCE

Significant difference is determined at ≥ 2-log or P < 0.05

TURNAROUND TIME

STANDARD

20 Days

CLINICAL RELEVANCE

THERAPEUTIC AREA

Infectious Disease

ADDITIONAL INFORMATION

BRAND

PDS

TESTING LOCATION

Taiwan - Taipei

OTHER INFORMATION

We will readily accommodate client-specified alterations. These studies are performed at our AAALAC accredited BSL-2 laboratory in Taipei, Taiwan. All aspects of this work are performed in general accordance with the Guide for the Care and Use of laboratory animals (National Academy Press, Washington, DC, 2011). The study protocol was approved by the Pharmacology Discovery Services IACUC and is performed with the oversight of veterinarians to assure the humane treatment of laboratory animals.